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Treatment of iron deficiency anemia in orthopedic surgery with
intravenous iron: efficacy and limits: a prospective study
Abstract
BACKGROUND: Preoperative anemia is frequent in patients undergoing orthopedic surgery. The
purpose of this study was to assess the preoperative increase of hemoglobin in iron deficiency anemia
patients treated with intravenous iron. 
METHODS: After obtaining written informed consent, 20 patients with iron deficiency anemia received
900 mg intravenous iron sucrose over 10 days starting 4 weeks before surgery. Changes of hemoglobin
and iron status were measured over 4 weeks and at discharge. In the last 11 patients, endogenous
erythropoietin was also measured. Data were analyzed using the Friedman test followed by pairwise
Wilcoxon signed rank tests with Bonferroni correction. 
RESULTS: Hemoglobin increased significantly (P < 0.0001) after intravenous iron treatment. Overall,
the mean maximum increase was 1.0 +/- 0.6 g/dl (range, 0.2-2.2 g/dl). Ferritin increased from 78 +/- 70
to 428 +/- 191 microg/l (P = 0.0001), ferritin index decreased from 2.7 +/- 2.4 to 1.5 +/- 1.0 (P =
0.0001), and soluble transferrin receptor decreased from 4.1 +/- 2.3 mg/l to 3.7 +/- 2.3 mg/l (P = 0.049),
whereas transferrin saturation (20.5 +/- 9.0 to 22.9 +/- 9.0%) and serum iron (13.3 +/- 4.6 to 13.1 +/- 4.5
microm) did not change significantly after intravenous iron treatment. Endogenous erythropoietin
decreased from 261 +/- 130 pg/ml to 190 +/- 49 pg/ml 2 weeks after intravenous iron treatment (P =
0.050, not significant after Bonferroni correction). No adverse events related to intravenous iron were
observed. The maximum increase of hemoglobin was observed 2 weeks after the start of intravenous
iron treatment, indicating that administration of intravenous iron 2-3 weeks before surgery may be
optimal. 
CONCLUSION: Treatment with intravenous iron allows correcting iron deficiency anemia before
elective surgery.
Anesthesiology 2007; 107:923–7 Copyright © 2007, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.
Treatment of Iron Deficiency Anemia in Orthopedic
Surgery with Intravenous Iron: Efficacy and Limits
A Prospective Study
Oliver M. Theusinger, M.D.,* Pierre-Franc¸ois Leyvraz, M.D.,† Urs Schanz, M.D.,‡ Burkhardt Seifert, Ph.D.,§
Donat R. Spahn, M.D., F.R.C.A.
Background: Preoperative anemia is frequent in patients
undergoing orthopedic surgery. The purpose of this study was
to assess the preoperative increase of hemoglobin in iron defi-
ciency anemia patients treated with intravenous iron.
Methods: After obtaining written informed consent, 20 pa-
tients with iron deficiency anemia received 900 mg intravenous
iron sucrose over 10 days starting 4 weeks before surgery.
Changes of hemoglobin and iron status were measured over 4
weeks and at discharge. In the last 11 patients, endogenous
erythropoietin was also measured. Data were analyzed using
the Friedman test followed by pairwise Wilcoxon signed rank
tests with Bonferroni correction.
Results: Hemoglobin increased significantly (P < 0.0001)
after intravenous iron treatment. Overall, the mean maximum
increase was 1.0  0.6 g/dl (range, 0.2–2.2 g/dl). Ferritin in-
creased from 78  70 to 428  191 g/l (P  0.0001), ferritin
index decreased from 2.7  2.4 to 1.5  1.0 (P  0.0001), and
soluble transferrin receptor decreased from 4.1  2.3 mg/l to
3.7  2.3 mg/l (P  0.049), whereas transferrin saturation (20.5
 9.0 to 22.9  9.0%) and serum iron (13.3  4.6 to 13.1  4.5
M) did not change significantly after intravenous iron treat-
ment. Endogenous erythropoietin decreased from 261  130
pg/ml to 190  49 pg/ml 2 weeks after intravenous iron treat-
ment (P  0.050, not significant after Bonferroni correction).
No adverse events related to intravenous iron were observed.
The maximum increase of hemoglobin was observed 2 weeks
after the start of intravenous iron treatment, indicating that
administration of intravenous iron 2–3 weeks before surgery
may be optimal.
Conclusion: Treatment with intravenous iron allows correct-
ing iron deficiency anemia before elective surgery.
PREOPERATIVE anemia is common among patients
scheduled to undergo elective surgery and may be pre-
dictive of allogeneic blood transfusion. Although the
prevalence varies according to surgical indication, re-
ports demonstrate that up to 35% of patients scheduled
to undergo joint arthroplasty have anemia.1,2 Likewise,
34% of patients scheduled to undergo noncardiac sur-
gery3 and as many as 76% of patients with Dukes stage D
colon cancer have low hemoglobin levels before sur-
gery.4 The prevalence of iron deficiency anemia among
patients scheduled to undergo elective surgery seems to
be around 30% among anemic patients.5,6
Preoperative anemia has significant consequences: Pa-
tients manifesting preoperative anemia are more likely to
receive allogeneic blood transfusions than patients with
a normal hemoglobin level.2 In addition, preoperative
anemia and blood transfusions are associated with a
higher incidence of postoperative infections and a
longer hospital stay.3
In patients with proven iron deficiency anemia, treat-
ment with intravenous iron seems to be the specific
treatment. However, the efficacy of high-dose intrave-
nous iron to correct preoperative anemia in elderly pa-
tients scheduled to undergo orthopedic surgery has not
been formally investigated so far.
The purpose of the current study was to assess the
increase of hemoglobin preoperatively in patients with
mild to moderate anemia and iron deficiency scheduled
to undergo elective major orthopedic surgery when
treated with intravenous iron.
Materials and Methods
The protocol of this study was approved by the local
ethics committee (President: Prof. Dr. M. Burnier, Com-
mission e´thique de la recherche clinique de la faculte´ de
me´decine of the University of Lausanne, Switzerland,
January 9, 2006, under No. 205/05).
Patients scheduled to undergo major elective orthope-
dic surgery such as knee or hip arthroplasty or back
surgery were screened for this study. They were seen
consecutively 5–6 weeks before their intervention and
were informed about this study. After written informed
consent was obtained, all specific information was col-
lected, and it was determined whether a patient met the
inclusion criteria without violating any of the exclusion
criteria. For each patient, the medical history, concomi-
tant medications, body weight and height, physical ex-
amination including vital signs, hematologic parameters
(hemoglobin, hematocrit, reticulocytes, mean corpuscu-
lar hemoglobin (MCH), mean corpuscular volume
(MCV), mean corpuscular hemoglobin concentration
(MCHC), vitamin B12, folic acid, iron indices (serum
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ferritin, transferrin saturation [TSAT], serum iron, solu-
ble transferrin receptor [sTfr]),7,8 C-reactive protein
(CRP), pregnancy test result (for premenopausal
women), and erythropoietin for the last 11 patients were
recorded.
The following inclusion criteria were used: age  18
yr, hemoglobin level at baseline for males 10.0–13.0 g/dl
and for females 10.0–12.0 g/dl, iron deficiency con-
firmed by either ferritin  100 g/l or 100–300 g/l
with TSAT  20% or soluble transferrin receptor (Mod-
ular P®, Soluble Transferrin Receptor 2148315; Roche
Diagnostics, Mannheim, Germany) for females 4.4 and
for males  5.5 or a ferritin index for CRP  5 of  3.2
and for CRP  5 of  2.0. Exclusion criteria were the
participation in another trial in the previous month,
pregnancy or lactation, known hypersensitivity to iron
sucrose, significant cardiovascular disease, e.g., unstable
angina, immunosuppressive or myelosuppressive ther-
apy, known history of hepatitis B or C or human immu-
nodeficiency virus, folate or vitamin B12 deficiency, CRP
 20 mg/l, active severe infection or malignancy, suspi-
cion of iron overload (ferritin 300 g/l and/or TSAT
50%), or autologous blood transfusion in the previous
month. No patient received erythropoietin or any iron
preparations in the previous month or during the study.
All patients had a workup by their general practitioners
in order not to miss a possible underlying malignancy to
their anemia and iron deficiency.
Patients who where included (total of 20 patients)
received three intravenous infusions of 300 mg iron as
iron sucrose (Venofer®; Vifor International Inc., Sankt
Gallen, Switzerland) over 90 min during a period of 10
days after baseline, except for male patients with a body
weight  70 kg and female patients with a body weight
 50 kg, for whom the total dose was calculated indi-
vidually according to the formula total iron deficit (mg)
 weight (kg)  (ideal hemoglobin [15 g/dl] – actual
hemoglobin [g/dl])  2.4  depot iron (500 mg)9 not
exceeding 900 mg. The infusion solution, consisting of
300 mg iron (III)–hydroxide sucrose, was diluted in 300
ml normal saline, 0.9%. Dilution took place immediately
before infusion.
In Switzerland, the maximum dose of intravenous iron
sucrose is 500 mg. Therefore, the dose of 300 mg intra-
venous iron sucrose is not off-label according to local
regulation. We limited the dose to 300 mg to avoid
adverse events.10
Hemoglobin was determined 1, 2, and 3 weeks after
the start of intravenous iron treatment and at follow-up
at hospital discharge or on postoperative day 14, which-
ever came first. sTfr was measured at 3 weeks after the
start of intravenous iron treatment and at follow-up. In
the last 11 patients, erythropoietin was measured at
baseline and 2 and 3 weeks after the start of intravenous
iron treatment. Transfusion needs and duration of stay
were also documented.
Statistical Analyses
No sample size analysis was performed because of the
lack of reliable data on the hematopoietic effect of high-
dose intravenous iron in patients scheduled to undergo
elective orthopedic surgery. A trial database within the
PheedIt® database system (version 3.0; SAS Institute Inc.,
Cary, NC) was used to store study data. In this database,
all records were entered from the case report forms and
the laboratory results of erythropoietin, which were
analyzed in an external laboratory. The statistical analy-
ses were performed using SPSS® (version 13; SPSS Inc.,
Chicago, IL). Continuous variables are summarized as
mean  SD and median with range where appropriate.
Changes of hemoglobin and endogenous erythropoietin
were analyzed using the Friedman test followed by pair-
wise post hoc comparisons using the Wilcoxon signed
rank test with Bonferroni correction. Continuous vari-
ables with two measurements were compared using the
Wilcoxon signed rank test. P values of 0.05 or less are
considered significant. Prevalence of anemia is pre-
sented with exact confidence interval (CI). Continuous
variables were transformed to normal distribution, and
CIs for the mean were computed. The limits of these CIs
then were retransformed to the original units and inter-
preted as CIs for the median.
Role of the Funding Source
The authors, in collaboration with the funding sources,
designed the study protocol. Data were collected on
specially designated case report forms and entered into
a database by a company assigned by Vifor International.
All data were verified by the authors and Vifor Interna-
tional before the database was closed for analysis.
Results
Over 7 months, 93 consecutive patients were screened
after written consent, of whom 20 (21.5%; 95% CI,
14–31%) were entered into the study and treated. Eight
subjects were male (40%), 12 were female (60%), 19
were white, and 1 was black. The mean age of the
patients was 71  10 yr, weight was 79  23 kg, height
was 169  8 cm, and body mass index was 27  6
kg/m2.
All patients screened had a hemoglobin  10 g/dl. We
only found iron deficiency anemia in the screened pa-
tients; no other type of anemia was detected, such as
folate or vitamin B12 deficiency. Patients with hemoglo-
bin between 10 and 13 g/dl (12 g/dl in women), indi-
cating mild to moderate anemia, were enrolled into this
study.
Hemoglobin increased significantly (P 0.0001, Fried-
man test) at 1, 2, and 3 weeks after the start of the
intravenous iron treatment (fig. 1A). Overall, the mean
maximum increase was 1.0  0.6 g/dl (range, 0.2–2.2
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g/dl; 95% CI for the mean, 0.8–1.3 g/dl). The highest
increase of hemoglobin was 2 weeks after the start of
intravenous treatment (P  0.0001, Wilcoxon signed
rank test). Four patients (20%), 12 patients (60%), and 4
patients (20%) had a maximum increase in hemoglobin
1, 2, and 3 weeks, respectively, after the start of intra-
venous iron treatment.
Ferritin levels also increased significantly (P  0.0001)
from 78 70 g/l at baseline to 428 191 g/l (median
increase, 638%; 95% CI, 523–958%) 3 weeks after the
start of intravenous iron treatment (fig. 1B). Endogenous
erythropoietin decreased after intravenous iron treat-
ment from 261  130 pg/ml at baseline to 190  49
pg/ml 2 weeks after the start of intravenous iron treat-
ment (P  0.050). This is, however, not significant after
Bonferroni correction. Median reduction of endogenous
erythropoietin at 2 and 3 weeks after the start of the
intravenous iron treatment was 11% (95% CI, 1–28%)
and 21% (95% CI, 5% increase to 46% reduction). Over-
all, the median maximal reduction was 33% (P  0.02;
95% CI, 13–50%; fig. 1C).
The ferritin index (ferritin index  sTfr/log ferritin)
decreased significantly (P  0.0001) from 2.7  2.4
(range, 1–11) at baseline to 1.5  1.0 (range, 1–5) 3
weeks after the start of intravenous iron treatment, and
sTfr (P  0.049) decreased from 4.1  2.3 g/ml at
baseline to 3.7  2.3 g/ml at week 3. TSAT (20.5  9.0
to 22.9 9.0%) and serum iron (13.3 4.6 to 13.1 4.5
M) did not change significantly after intravenous iron
treatment (table 1).
Eight of 20 patients (40%) required transfusions perio-
peratively. A total of 18 units of erythrocytes was trans-
fused (0.9  1.3 units per patient). The duration of
hospital stay for all patients was 12.6 3.8 days. Patients
receiving blood transfusions were in the hospital for
13.0  4.3 days and those not transfused were in the
hospital for 11.5  3.4 days.
There were three adverse events recorded, two uri-
nary tract infections and one infection of a leg. Although
there is concern that intravenous iron may increase the
risk of infection, we did not think that the three events
were related to the treatment with intravenous iron. The
single serious adverse event was a postoperative death
due to paralytic ileus with bronchial aspiration. This
event was also considered not to be related to the intra-
venous iron treatment 5 weeks before.
Discussion
We found a prevalence of iron deficiency anemia of
approximately 20% in patients screened and scheduled
to undergo major orthopedic surgery (knee and hip
prothesis, back surgery). Intravenous iron therapy suc-
ceeded in increasing the hemoglobin concentration.
However, because of the concomitant decrease in en-
dogenous erythropoietin, this increase was not sus-
tained.
The prevalence of preoperative anemia varies in differ-
ent populations from 5% up to 76% depending on the
underlying pathology, the population being screened,
socioeconomic status, and age.2,4,11–13 Furthermore,
varying definitions of anemia add to the variability. In
orthopedic surgery, one third of patients scheduled to
undergo elective arthroplasty procedures for osteoarthri-
tis are anemic. Goodnough et al.5 found that one third of
the anemic patients scheduled to undergo elective sur-
gery had iron deficiency anemia, and Basora et al.6
found, in 218 patients studied, 87 patients (39%) with
hemoglobin levels between 10 and 13 g/dl, of whom
Fig. 1. Changes of hemoglobin (A), ferritin (B), and erythropoi-
etin (C) concentration over time. * P  0.050, ** P < 0.017, *** P
< 0.001 versus start. iv  intravenous.
Table 1. Changes of Parameters and Their Significance
Baseline Week 2 Week 3
Hemoglobin, g/dl 11.9  0.8 12.8  0.8‡ 12.4  0.7†
Ferritin, g/l 78  70 428  191‡
sTfr, g/ml 4.1  2.3 3.7  2.3*
Epo, pg/ml 261  130 190  49* 189  75
Serum Fe, M 13.3  4.6 13.1  4.5
TSAT, % 20.5  9.0 22.9  9.0
Data are presented as mean  SD.
* P  0.050, † P  0.005, ‡ P  0.001 vs. baseline.
Epo  endogenous erythropoietin; Fe  iron; sTfr  soluble transferrin
receptor; TSAT  transferrin saturation.
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27% were anemic due to iron deficiency. Also, in a
prospective study of 9,482 patients scheduled to un-
dergo elective hip (n  3,920) or knee (n  5,562)
replacement, Bierbaum et al.1 reported that 35% had a
preoperative hemoglobin level  13 g/dl. Using a more
conservative definition of anemia (men, hemoglobin 
12.5 g/dl; women, hemoglobin 11.5 g/dl), Meyers et
al.14 described a 15% prevalence of preoperative anemia
in 225 patients undergoing hip arthroplasty. The clinical
relevance of preoperative anemia is that anemic patients
receive more allogeneic blood transfusions and may
have a higher incidence of postoperative infections and
a longer duration of hospitalization.3,15 In addition, Gur-
son et al.15 have shown that preoperatively, anemic
patients had an elevated mortality rate at 6 and 12
months. Therefore, correction of preoperative anemia
seems attractive.
Knowing the exact type of anemia allows physicians to
treat anemia specifically. Laboratory values such as MCV,
ferritin, and other parameters can help to classify and
differentiate between the mechanisms of preoperative
anemia such as nutritional anemia, iron deficiency ane-
mia, or other types.16 Microcytic anemia, most com-
monly caused by iron deficiency, is marked by reduc-
tions in erythrocyte parameters such as MCV, MCH, and
MCHC. Macrocytic anemia, characterized by an in-
creased MCV, is typically induced by medication, alco-
holism, or deficiencies in vitamin B12 or folate. Normo-
cytic anemia, on the other hand, may be caused by
nutritional deficiency, chronic kidney disease, hemoly-
sis, anemia of chronic disease, or primary bone marrow
disorders. With normocytic anemia, the MCV is within
normal limits, but the hemoglobin and hematocrit levels
are below normal.
Ioannou et al.17 have shown that iron deficiency is not
a sensitive marker for colorectal cancer, but the relative
risk of colorectal cancer is increased in the combined
presence of anemia and iron deficiency. For this reason,
anemic patients should have a workup if the origin of
anemia is undetermined.
Iron deficiency has an impact on mortality and mor-
bidity,18 and therefore, diagnostics and treatment are
important. Diagnostics of iron deficiency anemia include
hemoglobin, hematocrit, MCV, ferritin, TSAT, and CRP.
This should detect most of the patients who are iron
deficient. Because inflammation and infection modulate
ferritin and transferrin concentrations, we also analyzed
the sTfr, which is not modulated by infection or inflam-
mation and allows by the ratio of the sTfr value to the
logarithm of the ferritin value to determine iron defi-
ciency anemia.7 Of 93 screened patients, determining
the sTfr was only helpful in one case. In all of the other
cases, the sTfr did not provide any additional informa-
tion. Determining the sTfr therefore does not seem to be
required in the diagnosis of iron deficiency anemia on a
routine basis, but may be helpful in special rare situa-
tions.
In the current study group, iron stores were empty and
hemoglobin was low because of the lack of iron. The
intravenous iron given was in part directed toward he-
matopoiesis and into the iron stores. This may explain
why serum iron did not increase as a result of intrave-
nous iron treatment. The decrease of serum iron post-
operatively may be explained by perioperative blood
loss.
Stable TSAT may indicate that for certain patients, the
dose of 900 mg iron sucrose was insufficient, and cer-
tainly no iron overload was created.
Intravenous iron has been used in orthopedic surgery.
Cuenca et al.19 started with intravenous iron 3 days
before the operation in patients with a pertrochanteric
hip fracture and reported reduction in transfusion re-
quirements, duration of hospital stay, and incidence of
infections. However, the exact time course of the hemo-
globin response due to intravenous iron was not de-
scribed, and the described benefits were in the compar-
ison with a historic control group.
There are two main limitations of this study, the lack of
a control group and the limited number of patients
enrolled. Because of the lack of a control group in our
study, we compared our data with the data of the control
group and the treated group of Cuenca et al.19 The
transfusion requirements in the control group of the
study by Cuenca et al. were 1.3 1.3 and 0.9 1.2 units
in the treated group. Our rate was 0.9 1.3 units, which
is similar. The percentage of patients transfused in the
study by Cuenca et al. is 56% in the control group and
44% in the treated group, and we found a transfusion
rate of 40%. The duration of hospital stay was 14.3 3.6
and 12.6  4.4 days, which is comparable to 12.6  3.8
days for all patients in the current study. Interestingly,
transfused patients were hospitalized for 13.0 4.3 days
versus 11.5  3.4 days in patients without transfusions.
With only 20 patients studied, we may have had limited
power to detect an effect of intravenous iron treatment
on hemoglobin concentration. However, the sample size
was large enough to demonstrate that hemoglobin in-
creased as a result of intravenous iron treatment and that
this effect represented a mean maximum increase of 1.0
 0.6 g/dl (range, 0.2–2.2 g/dl; 95% CI for the mean,
0.8–1.3 g/dl).
Endogenous erythropoietin decreased in response to
the hemoglobin increase, possibly as a result of intrave-
nous iron; we speculate that this is why hemoglobin
concentration was not sustained despite filled iron
stores.
A similar decrease in endogenous erythropoietin has
been observed in the treatment of inflammatory bowel
disease with intravenous iron. This might be explained
by the fact that the erythropoietic effect of intravenous
iron seems to last 7–10 days, after which the iron is
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sequestered by the reticuloendothelial system.20 On the
other hand, a simple negative feedback could be at the
origin of the decrease of erythropoietin. However, the
interplay between hemoglobin concentration, intrave-
nous iron treatment, and endogenous erythropoietin is
still incompletely understood.
Conclusion
The prevalence of iron deficiency anemia is approxi-
mately 21% (95% CI, 14–31%) in patients screened and
scheduled to undergo major elective orthopedic surgery
(knee and hip prothesis, back surgery). Intravenous iron
(iron sucrose, 900 mg) is an efficacious treatment. Ideal
timing may be 2 weeks before surgery. Future random-
ized control studies are needed to assess the impact of
such treatment on outcome.
The authors thank Ve´ronique Serex (Secretary, Hoˆpital Orthope´dique de la
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